DK3365321T3 - Solabegron-zwitterion og anvendelser deraf - Google Patents
Solabegron-zwitterion og anvendelser deraf Download PDFInfo
- Publication number
- DK3365321T3 DK3365321T3 DK16858451.4T DK16858451T DK3365321T3 DK 3365321 T3 DK3365321 T3 DK 3365321T3 DK 16858451 T DK16858451 T DK 16858451T DK 3365321 T3 DK3365321 T3 DK 3365321T3
- Authority
- DK
- Denmark
- Prior art keywords
- solabegron
- zwitterion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245656P | 2015-10-23 | 2015-10-23 | |
| US201562245670P | 2015-10-23 | 2015-10-23 | |
| US201662345574P | 2016-06-03 | 2016-06-03 | |
| US201662345327P | 2016-06-03 | 2016-06-03 | |
| US201662345357P | 2016-06-03 | 2016-06-03 | |
| PCT/US2016/058516 WO2017070689A2 (en) | 2015-10-23 | 2016-10-24 | Solabegron zwitterion and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3365321T3 true DK3365321T3 (da) | 2024-01-15 |
Family
ID=58557973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16858451.4T DK3365321T3 (da) | 2015-10-23 | 2016-10-24 | Solabegron-zwitterion og anvendelser deraf |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10065922B2 (da) |
| EP (1) | EP3365321B1 (da) |
| CN (2) | CN108290824B (da) |
| CA (1) | CA3001850A1 (da) |
| DK (1) | DK3365321T3 (da) |
| ES (1) | ES2967863T3 (da) |
| FI (1) | FI3365321T3 (da) |
| IL (2) | IL310527A (da) |
| PL (1) | PL3365321T3 (da) |
| PT (1) | PT3365321T (da) |
| WO (1) | WO2017070689A2 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| EP3226849A4 (en) | 2014-12-03 | 2018-05-09 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| US10065922B2 (en) | 2015-10-23 | 2018-09-04 | Velicept Therapeutics, Inc. | Solabegron zwitterion and uses thereof |
| US10298650B2 (en) * | 2016-04-20 | 2019-05-21 | Vasona Networks, Inc. | Maximum sustainable encoding bit rates for video downloads |
| US12102638B2 (en) | 2017-06-06 | 2024-10-01 | Urovant Sciences Gmbh | Use of vibegron to treat overactive bladder |
| SG11202103662VA (en) | 2018-12-05 | 2021-06-29 | Urovant Sciences Gmbh | Vibegron for the treatment of overactive bladder symptoms |
| CN111925294A (zh) * | 2020-07-06 | 2020-11-13 | 济南大学 | 一种托特罗定帕莫酸盐及其制备方法 |
| CN117529310A (zh) * | 2021-03-31 | 2024-02-06 | B3Ar治疗股份有限公司 | 微粒化的索拉贝隆的组合物及其使用方法 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL267508A (da) | 1960-07-26 | |||
| DE2965655D1 (en) | 1978-06-28 | 1983-07-21 | Beecham Group Plc | Secondary amines, their preparation, pharmaceutical compositions containing them and their use |
| GB8519154D0 (en) | 1985-07-30 | 1985-09-04 | Ici Plc | Aromatic ethers |
| DE3934436A1 (de) | 1989-06-01 | 1991-04-18 | Thomae Gmbh Dr K | 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5061727A (en) | 1990-05-04 | 1991-10-29 | American Cyanamid Company | Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles |
| NO179246C (no) | 1991-11-20 | 1996-09-04 | Sankyo Co | Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav |
| WO1995033724A1 (en) | 1994-06-09 | 1995-12-14 | Glaxo Group Limited | Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists |
| US5677346A (en) | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
| ES2193266T3 (es) | 1995-10-26 | 2003-11-01 | Mitsubishi Pharma Corp | Compuestos de feniletanolamina, utiles como agonistas de beta3, procedimiento para su produccion e intermedios de su produccion. |
| US6123961A (en) | 1996-09-25 | 2000-09-26 | Bridge Pharma, Inc. | Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin |
| GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
| DK1126826T6 (da) | 1998-11-02 | 2019-06-24 | Alkermes Pharma Ireland Ltd | Multipartikel-modificeret-frigivelsessammensætning af methylphenidat |
| US20060240105A1 (en) | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
| DE19856167C1 (de) | 1998-12-05 | 2000-05-04 | Vetter & Co Apotheker | Nadelschutzanordnung für Spritzen, Karpulen und dergleichen Injektionsinstrumente |
| GB9929297D0 (en) | 1999-12-11 | 2000-02-02 | Glaxo Group Ltd | Process |
| US20030018061A1 (en) | 2000-01-28 | 2003-01-23 | Kohei Ogawa | Novel remedies with the use of beta 3 agonist |
| US6395762B1 (en) | 2000-07-17 | 2002-05-28 | American Home Products Corporation | Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
| US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6444685B1 (en) | 2000-07-17 | 2002-09-03 | Wyeth | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
| US7709677B2 (en) | 2001-01-31 | 2010-05-04 | Glaxosmithkline Llc | Process of preparing arylethanoldiamines |
| GB0102407D0 (en) * | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Process |
| US7034053B2 (en) | 2001-01-31 | 2006-04-25 | Smithkline Beecham Corporation | Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors |
| WO2002072033A2 (en) | 2001-03-13 | 2002-09-19 | Penwest Pharmaceuticals Co. | Chronotherapeutic dosage forms containing glucocorticosteroid |
| WO2003024483A1 (fr) | 2001-09-11 | 2003-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire |
| TW200800953A (en) | 2002-10-30 | 2008-01-01 | Theravance Inc | Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine |
| EP1424079A1 (en) | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| EP1682183A2 (de) | 2003-11-03 | 2006-07-26 | Boehringer Ingelheim International Gmbh | Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einem alpha antagonisten und/oder einen 5-alpha reduktase-hemmer |
| DE10352132A1 (de) | 2003-11-04 | 2005-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten |
| ATE435026T1 (de) | 2003-11-27 | 2009-07-15 | Develogen Ag | Verfahren zur prävention und behandlung von diabetes mit neurturin |
| WO2005061433A2 (en) * | 2003-12-23 | 2005-07-07 | Astellas Pharma Inc. | Aminoalcohol derivatives |
| WO2005065673A1 (en) | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Atomoxetine formulations |
| EP1550447A1 (en) | 2004-01-02 | 2005-07-06 | Schering Aktiengesellschaft | Menstrual cycle control and improvement of conception rates in females |
| WO2005077364A1 (ja) | 2004-02-18 | 2005-08-25 | Yamanouchi Pharmaceutical Co., Ltd. | ソリフェナシンの経皮投与製剤およびその経皮透過改善方法 |
| JP2008516909A (ja) | 2004-10-18 | 2008-05-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 前立腺及び下部泌尿生殖路の病気を治療するためのβ−３アゴニストの使用 |
| CA2606207C (en) | 2005-04-19 | 2014-11-18 | Smithkline Beecham (Cork) Limited | Pharmaceutical composition |
| EP1769792A1 (de) | 2005-09-30 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden |
| ITMI20061581A1 (it) | 2006-08-04 | 2008-02-05 | Univ Bari | Ligandi del recettore beta-3 adrenergico e loro uso in terapia |
| EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| US20100113469A1 (en) | 2007-03-29 | 2010-05-06 | Merck & Co., Inc. | Combination therapy for the treatment-of lower urinary tract symptoms |
| CN101652377A (zh) | 2007-04-02 | 2010-02-17 | 泰拉科斯有限公司 | 苄基化糖苷衍生物及其用法 |
| GB0714790D0 (en) | 2007-07-30 | 2007-09-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| ES2393525T3 (es) | 2007-11-02 | 2012-12-26 | Astellas Pharma Inc. | Composición farmacéutica para el tratamiento de la vejiga hiperactiva |
| PE20091825A1 (es) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
| EP2274296B1 (en) | 2008-04-04 | 2012-10-17 | Merck Sharp & Dohme Corp. | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
| EP2181707A1 (en) | 2008-11-04 | 2010-05-05 | Astellas Ireland Co., Ltd. | Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent |
| WO2010118291A2 (en) * | 2009-04-10 | 2010-10-14 | Auspex Pharmaceuticals, Inc. | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
| US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| WO2010129326A1 (en) | 2009-05-08 | 2010-11-11 | Merck Sharp & Dohme Corp. | Pyrrolidine-derived beta 3 adrenergic receptor agonists |
| US8586760B2 (en) | 2009-06-15 | 2013-11-19 | Auspex Pharmaceuticals, Inc. | Aminothiazole modulators of beta-3-adrenoreceptor |
| WO2011025690A1 (en) | 2009-08-27 | 2011-03-03 | Merck Sharp & Dohme Corp. | Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
| AU2010286694B2 (en) | 2009-08-27 | 2013-09-12 | Merck Sharp & Dohme Corp. | Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
| CA2774992A1 (en) | 2009-10-07 | 2011-04-14 | Merck Sharp & Dohme Corp. | Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
| MX2012006730A (es) | 2009-12-15 | 2012-07-30 | Metabolic Solutions Dev Co Llc | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas. |
| AU2010340061A1 (en) | 2009-12-15 | 2012-06-21 | Metabolic Solutions Development Company, Llc | PPAR-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases |
| CN102753170A (zh) | 2009-12-15 | 2012-10-24 | 新陈代谢解决方案开发公司 | 治疗糖尿病及其它代谢性疾病的ppar节制的噻唑烷二酮和组合 |
| JP5812500B2 (ja) | 2010-04-30 | 2015-11-17 | メルク・シャープ・エンド・ドーム・コーポレイション | 新規なβ３アドレナリン作動性受容体アゴニスト |
| KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| WO2016004056A1 (en) | 2014-07-03 | 2016-01-07 | Velicept Therapeutics, Inc. | Pharmaceutical combinations |
| US9907767B2 (en) * | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| SG187689A1 (en) * | 2010-08-03 | 2013-03-28 | Altherx Inc | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| WO2012154770A1 (en) | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder |
| WO2013119910A1 (en) | 2012-02-09 | 2013-08-15 | Altherx, Inc. | Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder |
| ES2394349B1 (es) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
| HK1208801A1 (en) | 2012-08-31 | 2016-03-18 | 安斯泰来制药株式会社 | Orally administered medical composition |
| US20150306170A1 (en) | 2012-11-21 | 2015-10-29 | Ferring B.V. | Composition for immediate and extended release |
| WO2014134005A2 (en) | 2013-02-26 | 2014-09-04 | Xenoport, Inc. | Method of making 1-(acyloxy)-alkyl carbamate compounds |
| WO2015120110A2 (en) * | 2014-02-07 | 2015-08-13 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
| EP3226849A4 (en) * | 2014-12-03 | 2018-05-09 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| US10065922B2 (en) | 2015-10-23 | 2018-09-04 | Velicept Therapeutics, Inc. | Solabegron zwitterion and uses thereof |
| US20170348263A1 (en) | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| US20170348288A1 (en) | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder |
| CN117529310A (zh) | 2021-03-31 | 2024-02-06 | B3Ar治疗股份有限公司 | 微粒化的索拉贝隆的组合物及其使用方法 |
-
2016
- 2016-10-24 US US15/332,956 patent/US10065922B2/en active Active
- 2016-10-24 CN CN201680069478.7A patent/CN108290824B/zh active Active
- 2016-10-24 IL IL310527A patent/IL310527A/en unknown
- 2016-10-24 DK DK16858451.4T patent/DK3365321T3/da active
- 2016-10-24 PL PL16858451.4T patent/PL3365321T3/pl unknown
- 2016-10-24 WO PCT/US2016/058516 patent/WO2017070689A2/en not_active Ceased
- 2016-10-24 CA CA3001850A patent/CA3001850A1/en active Pending
- 2016-10-24 IL IL258856A patent/IL258856B2/en unknown
- 2016-10-24 CN CN202111549024.9A patent/CN114230477A/zh active Pending
- 2016-10-24 PT PT168584514T patent/PT3365321T/pt unknown
- 2016-10-24 ES ES16858451T patent/ES2967863T3/es active Active
- 2016-10-24 FI FIEP16858451.4T patent/FI3365321T3/fi active
- 2016-10-24 EP EP16858451.4A patent/EP3365321B1/en active Active
-
2018
- 2018-06-26 US US16/018,945 patent/US10221126B2/en active Active
-
2019
- 2019-01-11 US US16/246,114 patent/US10844004B2/en active Active
-
2020
- 2020-10-22 US US17/077,446 patent/US11691944B2/en active Active
-
2023
- 2023-05-18 US US18/199,205 patent/US12435026B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170114005A1 (en) | 2017-04-27 |
| US20190185414A1 (en) | 2019-06-20 |
| CN108290824B (zh) | 2022-03-11 |
| IL258856A (en) | 2018-06-28 |
| EP3365321A4 (en) | 2019-06-05 |
| CA3001850A1 (en) | 2017-04-27 |
| US11691944B2 (en) | 2023-07-04 |
| FI3365321T3 (fi) | 2024-01-02 |
| ES2967863T3 (es) | 2024-05-06 |
| US12435026B2 (en) | 2025-10-07 |
| WO2017070689A2 (en) | 2017-04-27 |
| PT3365321T (pt) | 2024-01-12 |
| US20210317073A1 (en) | 2021-10-14 |
| US10065922B2 (en) | 2018-09-04 |
| US20180370902A1 (en) | 2018-12-27 |
| PL3365321T3 (pl) | 2024-03-25 |
| WO2017070689A3 (en) | 2017-07-20 |
| US20240124391A1 (en) | 2024-04-18 |
| EP3365321B1 (en) | 2023-12-13 |
| IL258856B1 (en) | 2024-03-01 |
| EP3365321A2 (en) | 2018-08-29 |
| CN114230477A (zh) | 2022-03-25 |
| US10844004B2 (en) | 2020-11-24 |
| IL258856B2 (en) | 2024-07-01 |
| CN108290824A (zh) | 2018-07-17 |
| US10221126B2 (en) | 2019-03-05 |
| IL310527A (en) | 2024-03-01 |
| HK1258038A1 (en) | 2019-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280863A (en) | Autotaxin inhibitors and uses thereof | |
| DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
| DK3368534T3 (da) | Valbenazin-ditosylat og polymorfer deraf | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3229838T3 (da) | Anti-C10orf54-antistoffer og anvendelser deraf | |
| DK3157552T3 (da) | Syntac-polypeptider og anvendelser deraf | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
| PL3265448T3 (pl) | Proleki riluzolu i ich zastosowanie | |
| DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
| DK3099172T3 (da) | Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf | |
| DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
| DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
| DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
| DK3236991T3 (da) | Fgf21-derivater og anvendelser deraf | |
| DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
| DK3256598T3 (da) | Svampestammer og anvendelsesfremgangsmåder | |
| DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
| DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf | |
| DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
| DK3337506T3 (da) | Kombinationer og anvendelser deraf | |
| DK3245219T3 (da) | Glypicanepitoper og anvendelser deraf | |
| DK3256479T3 (da) | 4-substituerede benzoxaborolforbindelser og anvendelser deraf | |
| DK3280405T3 (da) | Inhibitorer og anvendelser deraf |